DE3872878D1 - Behandlung von diabetes durch kombinierte insulinformen. - Google Patents

Behandlung von diabetes durch kombinierte insulinformen.

Info

Publication number
DE3872878D1
DE3872878D1 DE8888904864T DE3872878T DE3872878D1 DE 3872878 D1 DE3872878 D1 DE 3872878D1 DE 8888904864 T DE8888904864 T DE 8888904864T DE 3872878 T DE3872878 T DE 3872878T DE 3872878 D1 DE3872878 D1 DE 3872878D1
Authority
DE
Germany
Prior art keywords
insulin
function
liver
targeted
encapsulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8888904864T
Other languages
English (en)
Other versions
DE3872878T2 (de
Inventor
Walter Blair Geho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SDG Inc
Original Assignee
Technology Unlimited Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technology Unlimited Inc filed Critical Technology Unlimited Inc
Application granted granted Critical
Publication of DE3872878D1 publication Critical patent/DE3872878D1/de
Publication of DE3872878T2 publication Critical patent/DE3872878T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
DE8888904864T 1988-01-13 1988-05-13 Behandlung von diabetes durch kombinierte insulinformen. Expired - Lifetime DE3872878T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/143,180 US4863896A (en) 1984-05-03 1988-01-13 Diabetic control by combined insulin forms
PCT/US1988/001536 WO1989006540A1 (en) 1988-01-13 1988-05-13 Diabetic control by combined insulin forms

Publications (2)

Publication Number Publication Date
DE3872878D1 true DE3872878D1 (de) 1992-08-20
DE3872878T2 DE3872878T2 (de) 1992-12-03

Family

ID=22502938

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888904864T Expired - Lifetime DE3872878T2 (de) 1988-01-13 1988-05-13 Behandlung von diabetes durch kombinierte insulinformen.

Country Status (8)

Country Link
US (1) US4863896A (de)
EP (1) EP0358709B1 (de)
AT (1) ATE78169T1 (de)
AU (1) AU622370B2 (de)
DE (1) DE3872878T2 (de)
DK (1) DK452289A (de)
FI (1) FI894376A0 (de)
WO (1) WO1989006540A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420108A (en) * 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
WO1999016425A1 (en) * 1997-09-30 1999-04-08 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
US7169410B1 (en) 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
US6159931A (en) * 1998-09-29 2000-12-12 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
ES2465496T3 (es) 2003-01-06 2014-06-05 Emisphere Technologies, Inc. Terapia de insulina oral nocturna
US20050203001A1 (en) 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
CA2536393A1 (en) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Use of liposomes which are small unilamellar vesicles for the removal of an entity from a biological sample
ES2618028T3 (es) * 2004-07-19 2017-06-20 Biocon Limited Conjugados insulina-oligómero, formulaciones y usos de éstos.
EP3391876B1 (de) * 2005-05-23 2021-03-10 SDG, Inc. Lipidkonstrukt zur abgabe von insulin an ein säugetier
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
AU2008313248B2 (en) 2007-10-16 2012-04-26 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
WO2010080976A1 (en) * 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
CA2750269A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Crystalline insulin-conjugates
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
EP2391216A4 (de) 2009-01-28 2013-06-19 Smartcells Inc Exogen ausgelöste stoffe mit verzögerter freisetzung und ihre verwendung
PE20120583A1 (es) 2009-01-28 2012-05-19 Smartcells Inc Sistemas basados en conjugados para entrega farmacologica controlada
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
EP2598522A4 (de) 2010-07-28 2014-11-12 Smartcells Inc Rekombinante lektine, bindungsstellenmodifizierte lektine und anwendungen davon
WO2012015681A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
EP3052134B1 (de) 2013-10-04 2021-05-05 Merck Sharp & Dohme Corp. Auf glucose reagierende insulinkonjugate
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
KR20190124269A (ko) 2017-03-13 2019-11-04 에스디지,인코포레이티드 안정성이 증진된 지질 기반 나노입자
CA3136665A1 (en) * 2019-04-12 2020-10-15 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system

Also Published As

Publication number Publication date
US4863896A (en) 1989-09-05
DE3872878T2 (de) 1992-12-03
EP0358709A4 (de) 1990-03-08
ATE78169T1 (de) 1992-08-15
EP0358709A1 (de) 1990-03-21
EP0358709B1 (de) 1992-07-15
FI894376A0 (fi) 1989-09-15
AU1790588A (en) 1989-08-11
WO1989006540A1 (en) 1989-07-27
DK452289A (da) 1989-11-09
AU622370B2 (en) 1992-04-02
DK452289D0 (da) 1989-09-13

Similar Documents

Publication Publication Date Title
DE3872878D1 (de) Behandlung von diabetes durch kombinierte insulinformen.
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
DE69010336D1 (de) Pharmazeutische zusammensetzung zum abnehmen.
GEP20002146B (en) Therapeutic Peptide Derivatives
ES2060941T3 (es) Uso de nicotina para la fabricacion de un estuche para el tratamiento de condiciones susceptibles de dicho tratamiento.
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
SE8204874D0 (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
KR910005858A (ko) 지방산 요법
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
KR100271087B1 (en) Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
PT651654E (pt) Utilizacao de um dimero de lisozima para a preparacao de um medicamento para modular os mecanismos natutais de defesa
AR003979A1 (es) Administracion transdermica de vorozol.
Rosenthal Alterations in serum thyroxine with cerebral electrotherapy (electrosleep)
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
Katoh et al. Intraarterial lymphocytes injection for treatment of lymphedema
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
AR008155A1 (es) Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
SE9101341D0 (sv) New medicinal use
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
RU2076724C1 (ru) Способ лечения радиационных поражений
JPS6016921A (ja) 貼付薬
ATE328604T1 (de) Verwendung von wachstumshormon in niederen dosen
RU94020918A (ru) Способ лечения опсоменореи
邬亦贤 et al. THERAPEUTIC EFFECT AND MECHANISM OF ACUPUNCTURE AT NEIGUAN (P. 6) IN CHRONIC RHEUMATIC HEART DISEASE

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SDG, INC., WOOSTER, OHIO, US

8328 Change in the person/name/address of the agent

Free format text: TIEDTKE, BUEHLING, KINNE & PARTNER, 80336 MUENCHEN

8339 Ceased/non-payment of the annual fee